CA2996681C - Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy - Google Patents

Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy Download PDF

Info

Publication number
CA2996681C
CA2996681C CA2996681A CA2996681A CA2996681C CA 2996681 C CA2996681 C CA 2996681C CA 2996681 A CA2996681 A CA 2996681A CA 2996681 A CA2996681 A CA 2996681A CA 2996681 C CA2996681 C CA 2996681C
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
group
independently selected
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2996681A
Other languages
English (en)
French (fr)
Other versions
CA2996681A1 (en
Inventor
Brian Desmond Palmer
Lai-Ming Ching
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of CA2996681A1 publication Critical patent/CA2996681A1/en
Application granted granted Critical
Publication of CA2996681C publication Critical patent/CA2996681C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2996681A 2015-08-27 2016-08-25 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy Active CA2996681C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ711514 2015-08-27
NZ71151415 2015-08-27
PCT/NZ2016/050135 WO2017034420A1 (en) 2015-08-27 2016-08-25 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Publications (2)

Publication Number Publication Date
CA2996681A1 CA2996681A1 (en) 2017-03-02
CA2996681C true CA2996681C (en) 2024-04-09

Family

ID=58100623

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2996681A Active CA2996681C (en) 2015-08-27 2016-08-25 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Country Status (9)

Country Link
US (2) US11414428B2 (https=)
EP (1) EP3350188B1 (https=)
JP (2) JP7334041B2 (https=)
KR (1) KR20180048798A (https=)
CN (1) CN108349997B (https=)
AU (2) AU2016312848A1 (https=)
CA (1) CA2996681C (https=)
WO (1) WO2017034420A1 (https=)
ZA (1) ZA201800787B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
WO2018223969A1 (zh) * 2017-06-05 2018-12-13 复旦大学 N-苄基色胺酮类衍生物作为色氨酸双加氧酶(tdo)抑制剂的用途
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
CN112823036B (zh) * 2018-07-03 2024-11-08 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
JP2025507981A (ja) 2022-03-04 2025-03-21 アンティド セラピューティクス インターナショナル ソシエテ ア レスポンサビリテ リミティー トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の二重阻害剤と療法におけるそれらの使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001255410A1 (en) 2000-04-14 2001-10-30 Corvas International, Inc. Substituted hydrazinyl heteroaromatic inhibitors of thrombin
US20070197610A1 (en) 2004-03-16 2007-08-23 Janssen Pharmaceutica N.V. Benzisoxazoles
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
DE102005018389A1 (de) 2005-04-20 2006-10-26 Sanofi-Aventis Deutschland Gmbh Azolderivate als Inhibitoren von Lipasen und Phospholipasen
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE102005026194A1 (de) 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
BRPI1009428A2 (pt) 2009-03-10 2016-03-01 Gruenenthal Gmbh 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
WO2011100614A1 (en) 2010-02-11 2011-08-18 Vanderbilt University BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
PL2595995T3 (pl) 2010-07-22 2016-05-31 Basf Se Chwastobójcze izoksazolo[5,4-b]pirydyny
JP2015504889A (ja) 2012-01-12 2015-02-16 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 除草性イソオキサゾロ［５，４−ｂ］ピリジン
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
CN105209449B (zh) 2013-03-14 2019-02-01 库拉德夫制药私人有限公司 犬尿氨酸途径的抑制剂
WO2015082499A2 (en) 2013-12-03 2015-06-11 Iomet Pharma Ltd Pharmaceutical compound
AU2015302908B2 (en) * 2014-08-13 2020-02-13 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
RU2619120C1 (ru) 2016-06-06 2017-05-12 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" 5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике

Also Published As

Publication number Publication date
CA2996681A1 (en) 2017-03-02
ZA201800787B (en) 2025-08-27
AU2016312848A1 (en) 2018-03-29
AU2021212003B2 (en) 2023-09-14
EP3350188A1 (en) 2018-07-25
JP2018525430A (ja) 2018-09-06
CN108349997B (zh) 2025-06-10
WO2017034420A1 (en) 2017-03-02
US20220411438A1 (en) 2022-12-29
KR20180048798A (ko) 2018-05-10
CN108349997A (zh) 2018-07-31
EP3350188A4 (en) 2019-04-03
JP7334041B2 (ja) 2023-08-28
US20180244692A1 (en) 2018-08-30
AU2021212003A1 (en) 2021-08-26
US11414428B2 (en) 2022-08-16
JP2022033753A (ja) 2022-03-02
HK1258665A1 (en) 2019-11-15
EP3350188B1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
CA2996681C (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
US12508268B2 (en) Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
EP4004002B1 (en) Macrocyclic compounds as sting agonists and methods and uses thereof
JP6830948B2 (ja) Ｍｉｄｈ１阻害剤としての縮合イミダゾール
ES2545135T3 (es) Imidazopiridinas sustituidas y compuestos intermedios de las mismas
TW201245194A (en) Triazolopyridines
HK1258665B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
TW201938149A (zh) 用於治療癌症的選擇性組蛋白去乙醯酶3 (hdac3)抑制劑及免疫治療劑之組合
HK1238549A1 (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
HK1238549B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
HK40074766A (en) Macrocyclic compounds as sting agonists and methods and uses thereof
CZ419199A3 (cs) Kyanoguanidiny jako inhibitory buněčné proliferace
CZ9904239A3 (cs) Kyanoamidiny jako inhibitory buněčné proliferace
HK1178153A1 (zh) 三唑并吡啶
CZ9904237A3 (cs) Kyanoguanidiny jako inhibitory buněčné proliferace

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210816

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250204

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250811

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250811

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251210